Bristol-Myers 4th-qtr boosted by Opdivo and Eliquis

US pharma major Bristol-Myers Squibb (NYSE: BMY) today reported results for the fourth quarter and full year of 2018 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robust operating performance across the portfolio.

Fourth quarter 2018 revenue was $6.0 billion, an increase of 10% compared to the same period a year ago, and beating analysts’ estimates of $5.95 billion. Revenues increased 12% when adjusted for foreign exchange impact. Full year revenues were up 9% at $22.6 billion.

The company reported net earnings attributable to Bristol-Myers Squibb of $1.2 billion, or $0.73 per share, in the fourth quarter, compared to a net loss of $2.3 billion, or $1.42 per share, for the same period in 2017. Non-generally-accepted accounting principles (GAAP) EPS was $0.94, beating consensus forecasts of $0.86. Full year non-GAAP diluted EPS was up 32% at $3.98.